Companies · Biotechnology

Aadi Bioscience, Inc.

MORRISTOWN · Biotechnology

Diligence memoA one-page analyst read on Aadi Bioscience, Inc. — recommendation, valuation, rhythm, risks.
$451.8M
Total raised · real
5
Rounds
1.4×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Aadi Bioscience, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.99× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
  • Within the normal band (99% of peer median) for its niche.
Active
  • Last raise 16 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Aadi Bioscience, Inc. is one of 4291 Biotechnology companies tracked from MORRISTOWN. By capital raised it ranks among the largest (ahead of 99% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
17
Investors (latest)
2025-03-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2017-03-15 Raised $42M (real) Modeled valuation $1.7B (est)$42M$1.7BSeries C2017Series C · 2021-08-26 Raised $83M (real) Modeled valuation $2.2B (est)$83M$2.2BSeries C2021Series D+ · 2021-08-26 Raised $155M (real) Modeled valuation $4.4B (est)$155M$4.4BSeries D+2021Series D+ · 2022-09-26 Raised $72M (real) Modeled valuation $1.4B (est)$72M$1.4BSeries D+2022Series D+ · 2025-03-04 Raised $100M (real) Modeled valuation $878M (est)$100M$878MSeries D+2025+$83M+$155M+$72M+$100MCumulative $452M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$41.8M · 2017
Series C extension$82.5M · 2021
Series D+$155.0M · 2021
Series D+ extension$72.5M · 2022
Series D+ extension$100.0M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$878.4M
Base estimate est.
$453.3M
Conservative case
$1.1B
Upside case
$833.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series C · modeled $1.7B · 2017-03-152017Series C · modeled $2.2B · 2021-08-26Series D+ · modeled $4.4B · 2021-08-26Series D+ · modeled $1.4B · 2022-09-26Series D+ · modeled $878.4M · 2025-03-042025
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
1.3 yr
Elapsed time used
1.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$56.7M/yr
Capital velocity
9.3 yr
On record since
2017
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 63× above median
This company$451.8M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.8× of median
This company$100.0M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 14× above median
This company$878.4M
Sector median$64.2M

Raised more than 99% of sector peers (real $). Modeled value above 88% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #18 of 33.

This companyCohort peer
$100.0M$1.0B$10.0B$100.0M$1.0BCapital raised (log)Kriya Therapeutics, Inc. · Series D+ Raised $870.3M · modeled $2.5B (est)Pathos AI, Inc. · Series D+ Raised $365.0M · modeled $2.4B (est)Sensei Biotherapeutics, Inc. · Series D+ Raised $348.9M · modeled $2.2B (est)Odyssey Therapeutics, Inc. · Series D+ Raised $590.9M · modeled $1.7B (est)Rhodenergy An Environmental Co Corp · Series D+ Raised $250.0M · modeled $1.7B (est)Tectonic Therapeutic, Inc. · Series D+ Raised $333.1M · modeled $1.7B (est)Lumicell, Inc. · Series D+ Raised $331.1M · modeled $1.7B (est)MapLight Therapeutics, Inc. · Series D+ Raised $356.2M · modeled $1.5B (est)SAB Biotherapeutics, Inc. · Series D+ Raised $182.5M · modeled $1.4B (est)Immunic, Inc. · Series D+ Raised $514.4M · modeled $1.3B (est)Predictive Oncology Inc. · Series D+ Raised $280.1M · modeled $1.3B (est)Vascular Perfusion Solutions, Inc. · Series D+ Raised $154.9M · modeled $1.2B (est)Aadi Bioscience, Inc. (this company) Raised $451.8M · modeled $878.4M (est)Aadi Bioscience, Inc.
CompanyStageRaised · realValue · estvs peer med.
Kriya Therapeutics, Inc.Series D+$870.3M$2.5B2.79×
Pathos AI, Inc.Series D+$365.0M$2.4B2.70×
Sensei Biotherapeutics, Inc.Series D+$348.9M$2.2B2.53×
Odyssey Therapeutics, Inc.Series D+$590.9M$1.7B1.94×
Rhodenergy An Environmental Co CorpSeries D+$250.0M$1.7B1.89×
Tectonic Therapeutic, Inc.Series D+$333.1M$1.7B1.89×
Lumicell, Inc.Series D+$331.1M$1.7B1.89×
MapLight Therapeutics, Inc.Series D+$356.2M$1.5B1.65×
SAB Biotherapeutics, Inc.Series D+$182.5M$1.4B1.53×
Immunic, Inc.Series D+$514.4M$1.3B1.45×
Predictive Oncology Inc.Series D+$280.1M$1.3B1.42×
Vascular Perfusion Solutions, Inc.Series D+$154.9M$1.2B1.37×
Aadi Bioscience, Inc. this companySeries D+$451.8M$878.4M0.99×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$41.8M2017-03-15$278.9M$1.7B90%
Series C$82.5M2021-08-26$550.0M$2.2B90%
Series D+$155.0M2021-08-26$1.3B$4.4B90%
Series D+$72.5M2022-09-26$604.2M$1.4B90%
Series D+$100.0M2025-03-04$833.4M$878.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$41.8M2017-03-15
    • First recorded raise — entered as Series C.
    • 264 investors on this round.
  2. Series C$82.5M2021-08-26
    • Raised again after 53 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 15 investors on this round.
  3. Series D+$155.0M2021-08-26
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× larger than the prior — scaling up.
    • 31 investors on this round.
  4. Series D+$72.5M2022-09-26
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  5. Series D+$100.0M2025-03-04
    • Raised again after 29 mo — slower than the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 17 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~24mo cadence
$137.9M
Modeled next size est.range $100.0M$220.7M
1.4×
Last step-up
$56.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Emma Reeve3 other2021-08
Paul M. Weiss3 other2017-03
Neil Desai2 other2021-08
Anupam Dalal1 other2021-08
Behzad Aghazadeh1 other2022-09
Caley Castelein1 other2021-08
Caley M. Castelein1 other2017-03
Chau M. Khuong1 other2017-03
David Dornan1 other2025-03
Joseph Gardner1 other2017-03
Lance Thibault1 other2021-08
Mohammad Hirmand1 other2025-03
Scott Giacobello1 other2022-09
Steven M. Prelack1 other2017-03
Anupam M. Dalal2017-03
Baiteng Zhao2025-03
Brendan Delaney2022-09
Bryan Ball2025-03
Dave Lennon2025-03
James M. Murphy2017-03
Karin Hehenberger2022-09
Karin Heneberger2021-08
Kevin G. Peters2017-03
Loretta Itri2022-09
Registry & provenance

Aadi Bioscience, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1422142
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cardurion Pharmaceuticals, Inc.BiotechnologySeries D+$431.7M$2.8Bnetwork1 shared operator · same sector · same stage
Arcellx, Inc.BiotechnologySeries D+$272.8M$1.8Bnetwork1 shared operator · same sector · same stage
Avenzo Therapeutics, Inc.BiotechnologySeries D+$270.6M$355.3Mnetwork1 shared operator · same sector · same stage
Akebia Therapeutics, Inc.BiotechnologySeries A$25.9M$504.1Mnetwork2 shared operators · same sector
Autobahn Therapeutics, Inc.BiotechnologySeries D+$100.8M$1.1Bnetwork1 shared operator · same sector · same stage
Inscripta, Inc.BiotechnologySeries D+$473.9M$509.2Msame sector · same stage
Ptc Therapeutics, Inc.BiotechnologySeries D+$483.4M$591.1Msame sector · same stage
Impulse Dynamics N.V.BiotechnologySeries D+$417.3M$747.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aakha Biologics, Inc.BiotechnologyPre-Seed$3.5M84%
Bioscience Americas, LLCBiotechnologySeries A$4.3M84%
BCD Bioscience, Inc.BiotechnologySeries A$188.9M84%
Cubed Biotech Inc.BiotechnologyPre-Seed$1.7M82%
AavantiBio, Inc.BiotechnologySeries C$1.5B82%
Aloft Biotechnologies, Inc.BiotechnologyPre-Seed$398K82%
Acesis Holdings Corp.BiotechnologySeed$15.2M82%
Arkis BioSciences Inc.BiotechnologySeries A$162.1M81%
Frequently asked
How much funding has Aadi Bioscience, Inc. raised?
Aadi Bioscience, Inc. has raised approximately $451.8M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Aadi Bioscience, Inc.'s estimated valuation?
Provath's modeled valuation for Aadi Bioscience, Inc. is approximately $878.4M (modeled range $453.3M–$1.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Aadi Bioscience, Inc. at?
Aadi Bioscience, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Tue Mar 04.
What does Aadi Bioscience, Inc. do and where is it based?
Aadi Bioscience, Inc. operates in the Biotechnology sector, based in MORRISTOWN.
Explore related

See where Aadi Bioscience, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Aadi Bioscience, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.